Overview

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Status:
Recruiting

Trial end date:
2023-01-20

Target enrollment:

Participant gender:

Summary

This is a multicentre, randomised, open-label, parallel-group, active-controlled, phase IV study to assess the reduction of daily Symbicort® maintenance to anti-inflammatory reliever treatment only in participants with severe eosinophilic asthma on Fasenra® treatment, while maintaining asthma control.

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Albuterol
Anti-Inflammatory Agents
Benralizumab
Budesonide
Budesonide, Formoterol Fumarate Drug Combination
Formoterol Fumarate